One Novel Anxiolytic Mechanism, Three Gateways: What a Central Monoaminergic Candidate's Regulatory Path Reveals About Parallel Health Canada, FDA, and EMA Clinical Trial Authorization

Generalized anxiety disorder (GAD) remains a therapeutic area with a limited number of recently approved mechanisms, and new, orally administered small-molecule candidates acting on central monoaminergic pathways continue to be investigated as alternatives or adjuncts to existing selective serotonin and serotonin-norepinephrine reuptake inhibitors. This article uses a fully hypothetical new chemical entity and a fictional sponsor to compare the Clinical Trial Application (CTA) process required by Health Canada, the Investigational New Drug (IND) process required by the U.S. Food and Drug Administration, and the Clinical Trial Application process required by the European Medicines Agency under Regulation (EU) No 536/2014, using a Phase 2, randomized, placebo-controlled dose-ranging trial in adults with moderate-to-severe GAD as the illustrative scenario. The comparison traces how the Common Technical Document's harmonized Modules 2 through 5 carry the shared scientific case across all three regions, while each jurisdiction's administrative layer imposes distinct requirements, including the heightened attention every region's psychiatry-focused review division gives to suicidality monitoring and central nervous system safety signals for any new anxiolytic candidate. The article addresses the operational challenges specific to a central nervous system program conducted across Canada, the United States, and the European Union, the ways artificial intelligence tools are used, and can responsibly be used, in preparing and administering this kind of regulatory package, and closes with recommendations for regulatory operations teams managing novel psychiatric drug candidates across these three jurisdictions.Keywords: generalized anxiety disorder; central nervous system small molecule; Clinical Trial Application; Investigational New Drug; Regulation (EU) No 536/2014; suicidality monitoring; regulatory artificial intelligence